Sleep-disordered breathing and respiratory failure in acid maltase deficiency
Abstract
Background: Sleep-disordered breathing (SDB) and respiratory failure (RF) are complications of acid maltase deficiency (AMD), a rare hereditary myopathy. Objective: To define the relationship between lung and respiratory muscle function, to establish incidence and patterns of SDB, and to determine daytime predictors of SDB. Methods: Sitting and supine lung and respiratory muscle function tests were obtained in 27 subjects with juvenile and adult AMD (aged 39 ± 19 years) and compared with outcomes of polysomnography. Results: Ventilatory restriction was present in 17/27 subjects. Inspiratory vital capacity (IVC) correlated (p < 0.005) with peak inspiratory muscle pressure (PIP, R = 0.61), respiratory muscle strain (P0.1/P0.1max, R = −0.68), and gas exchange by day (PaO2: R = 0.71; PaCO2: R = −0.64) and night (SaO2: R = 0.73; PtcCO2: R = −0.75). Diaphragm weakness (DW) was present in 13 subjects, 10 of whom had hypercapnic RF (PaCO2 65 ± 7 mm Hg), and was associated with longer disease course. SDB was found in 13 subjects, 12 with DW. It was characterized by REM-sleep hypopneas that, as ventilatory restriction worsened, were complemented by hypoventilation (PtcCO2 > 50 mm Hg) first in REM sleep, then in non-REM sleep (p < 0.005). SDB was predicted by DW (sensitivity 80%, specificity 86%) and nocturnal hypoventilation by IVC < 40% (sensitivity 80%, specificity 93%). Noninvasive ventilation, instituted for daytime respiratory failure or nocturnal hypoventilation, normalized daytime and nocturnal gas exchange (p < 0.005). Conclusion: Vital capacity correlates with respiratory muscle function in AMD. Diaphragm weakness is the major cause of SDB and RF. SDB and nocturnal hypoventilation are predictable from daytime function tests.
Get full access to this article
View all available purchase options and get full access to this article.
References
1.
Reuser AJ, Kroos M, Willemsen R, Swallow D, Tager JM, Galjaard H. Clinical diversity in glycogenosis type II. Biosynthesis and in situ localization of acid alpha-glucosidase in mutant fibroblasts. J Clin Invest . 1987; 79: 1689–1699.
2.
Reuser AJ, Koster JF, Hoogeveen A, Galjaard H. Biochemical, immunological, and cell genetic studies in glycogenosis type II. Am J Hum Genet . 1978; 30: 132–143.
3.
Reuser AJ, Kroos MA, Hermans MM, et al. Glycogenosis type II (acid maltase deficiency). Muscle Nerve . 1995; 3: S61–S69.
4.
Dubowitz V. Metabolic myopathies I: Glycogenoses. In: Dubowitz V. Muscle disorders in childhood. 2nd ed. London: WB Saunders Co Ltd, 1995;177–210.
5.
Inoue S, Nakamura T, Hasegawa K, et al. Pulmonary hypertension due to glycogen storage disease type II (Pompe’s disease): a case report [in Japanese]. J Cardiol . 1989; 19: 323–332.
6.
Keunen RW, Lambregts PC, Op de Cool AA, Joosten EM. Respiratory failure as initial symptom of acid maltase deficiency. J Neurol Neurosurg Psychiatry . 1984; 47: 549–552.
7.
Kim DG, Jung K, Lee MK, et al. A case of juvenile form Pompe’s disease manifested as chronic alveolar hypoventilation. J Korean Med Sci . 1993; 8: 221–224.
8.
Moufarrej NA, Bertorini TE. Respiratory insufficiency in adult-type acid maltase deficiency. South Med J . 1993; 86: 560–567.
9.
Rosenow EC, Engel AG. Acid maltase deficiency in adults presenting as respiratory failure. Am J Med . 1978; 64: 485–491.
10.
Sander HW, Menkes DL, Hood DC, Williams DA. A 60-year-old woman with weakness, fatigue, and acute respiratory failure: case report and discussion of the differential diagnosis. Mil Med . 1998; 163: 715–718.
11.
Howard RS, Wiles CM, Hirsch NP, Spencer GT. Respiratory involvement in primary muscle disorders: assessment and management. Q J Med . 1993; 86: 175–189.
12.
Sivak ED, Salanga VD, Wilbourn AJ, Mitsumoto H, Golish J. Adult-onset acid maltase deficiency presenting as diaphragmatic paralysis. Ann Neurol . 1981; 9: 613–615.
13.
Margolis ML, Howlett P, Goldberg R, Eftychiadis A, Levine S. Obstructive sleep apnea syndrome in acid maltase deficiency. Chest . 1994; 105: 947–949.
14.
Lopes JM, Tabachnik E, Müller NL, Levison H, Bryan AC, Agusti AG. Total airway resistance and respiratory muscle activity during sleep. J Appl Physiol . 1983; 773–777:
15.
Van Lunteren E, Kaminski H. Disorders of sleep and breathing during sleep in neuromuscular disease. Sleep Breathing . 1999; 3: 23–30.
16.
Khan Y, Heckmatt JZ. Obstructive apneas in Duchenne muscular dystrophy [see comments]. Thorax . 1994; 49: 157–161.
17.
Bye PT, Ellis ER, Issa FG, Donnelly PM, Sullivan CE. Respiratory failure and sleep in neuromuscular disease. Thorax . 1990; 45: 241–247.
18.
Gay PC, Westbrook PR, Daube JR, Litchy WJ, Windebank AJ, Iverson R. Effects of alterations in pulmonary function and sleep variables on survival in patients with amyotrophic lateral sclerosis. Mayo Clin Proc . 1991; 66: 686–694.
19.
Labanowski M, Schmidt-Nowara W, Guilleminault C. Sleep and neuromuscular disease: frequency of sleep-disordered breathing in a neuromuscular disease clinic population [see comments]. Neurology . 1996; 47: 1173–1180.
20.
Simonds AK, Muntoni F, Heather S, Fielding S. Impact of nasal ventilation on survival in hypercapnic Duchenne muscular dystrophy. Thorax . 1998; 53: 949–952.
21.
Zapletal A, Paul T, Smanek M. Die Bedeutung heutiger Methoden der Lungenfunktionsdiagnostik zur Feststellung einer Obstruktion derr Atemwege bei Kindern und Jugendlichen. Z Ekrg Atem Org . 1977; 1977: 343.
22.
Quanjer PH, Tammeling GJ, Cotes JE, Peterson OF, Peslin R, Ernault JC. Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests. European Community for Steel and Coal Luxembourg. Eur Respir J Suppl . 1993; 16: 5–40.
23.
Castile RG. Pulmonary function testing in children. In: Chernick V, Boat TF, Kendig EL, eds. Kendig’s disorders of the respiratory tract in children. Philadelphia: WB Saunders Co, 1998: 196–214.
24.
Mier-Jedrzejowicz A, Brophy C, Moxham J, Green M. Assessment of diaphragm weakness. Am Rev Respir Dis . 1988; 137: 877–883.
25.
American Thoracic Society. Indications and standards for cardiopulmonary sleep studies. Medical Section of the American Lung Association. Am Rev Respir Dis . 1989; 139: 559–568.
26.
Raben N, Nagaraju K, Lee E, et al. Targeted disruption of the acid alpha-glucosidase gene in mice causes an illness with critical features of both infantile and adult human glycogen storage disease type II. J Biol Chem . 1998; 273: 19086–19092.
27.
Phillips MF, Smith PE, Carroll N, Edwards RH, Calverley PM. Nocturnal oxygenation and prognosis in Duchenne muscular dystrophy. Am J Respir Crit Care Med . 1999; 160: 198–202.
28.
Vianello A, Bevilacqua M, Salvador V, Cardaioli C, Vincenti E. Long-term nasal intermittent positive pressure ventilation in advanced Duchenne’s muscular dystrophy [see comments]. Chest . 1994; 105: 445–448.
29.
Bach JR. Perspectives of nasal ventilation: indications, methods and complementary techniques for patients with neuromuscular disease. Eur Respir Rev . 1993; 3: 243–244.
30.
Simonds AK. Nasal intermittent positive pressure ventilation in neuromuscular and chest wall disease. Monaldi Arch Chest Dis . 1993; 48: 165–168.
Information & Authors
Information
Published In
Copyright
© 2001.
Publication History
Received: February 23, 2001
Accepted: May 17, 2001
Published online: October 9, 2001
Published in print: October 9, 2001
Authors
Metrics & Citations
Metrics
Citation information is sourced from Crossref Cited-by service.
Citations
Download Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.
Cited By
- Effectiveness of Respiratory Muscle Training in Pompe Disease: A Systematic Review and Meta-Analysis, Children, 11, 10, (1209), (2024).https://doi.org/10.3390/children11101209
- An expert rule-based approach for identifying infantile-onset Pompe disease patients using retrospective electronic health records, Scientific Reports, 14, 1, (2024).https://doi.org/10.1038/s41598-024-72259-5
- Monitoring and Management of Respiratory Function in Pompe Disease: Current Perspectives, Therapeutics and Clinical Risk Management, Volume 19, (713-729), (2023).https://doi.org/10.2147/TCRM.S362871
- Assessment of sleep-disordered breathing, Pulmonary Assessment and Management of Patients with Pediatric Neuromuscular Disease, (59-72), (2023).https://doi.org/10.1016/B978-0-323-95747-2.00016-1
- Pulmonary pathophysiology of neuromuscular disease, Pulmonary Assessment and Management of Patients with Pediatric Neuromuscular Disease, (23-36), (2023).https://doi.org/10.1016/B978-0-323-95747-2.00009-4
- Survey on the management of Pompe disease in routine clinical practice in Spain, Orphanet Journal of Rare Diseases, 17, 1, (2022).https://doi.org/10.1186/s13023-022-02574-5
- A Systematic Review investigating the Effectiveness of Exercise training in Glycogen Storage Diseases, Therapeutic Advances in Rare Disease, 3, (2022).https://doi.org/10.1177/26330040221076497
- Sleep-related breathing disorder in non-infectious pulmonary complications after pediatric allogeneic stem cell transplantation, Pediatric Research, 93, 7, (1983-1989), (2022).https://doi.org/10.1038/s41390-022-02339-7
- Manifestations pulmonaires des maladies héréditaires du métabolisme, Revue des Maladies Respiratoires, 39, 9, (758-777), (2022).https://doi.org/10.1016/j.rmr.2022.09.002
- Extra-muscular manifestations in GNE myopathy patients: A nationwide repository questionnaire survey in Japan, Clinical Neurology and Neurosurgery, 212, (107057), (2022).https://doi.org/10.1016/j.clineuro.2021.107057
- See more
Loading...
View Options
Login options
Check if you have access through your login credentials or your institution to get full access on this article.
Personal login Institutional LoginPurchase Options
The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.
If you need immediate support or to place an order, please call or email customer service:
- 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
- 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
- [email protected]
We appreciate your patience during this time and apologize for any inconvenience.